@hashemdbouk profile picture
Hashem A. Dbouk @hashemdbouk

Science/medical writer, major disease states: oncology, COPD, inflammatory disorders. Kinase afficionado. YNWA. All opinions are my own.

Joined July 2013
  • Tweets 1,227
  • Following 355
  • Followers 227
27 Photos and videos
Pinned Tweet
Hashem A. Dbouk@hashemdbouk
31 Dec 2020
After 5 years since I initiated this project, my article "WNK1 Kinase Controls Podocyte Cytoskeletal and Glomerular Capillary Wall Structure and Elasticity" is finally accepted #WNK #kinase #cellbiology #cellsignaling #kidney #glomerulus #science frontiersin.org/article/10.3…
Attention Virginia Liverpool Fans: If you would like to show your love of LFC on your car, you can now pre-register for an Official Liverpool Supporters Club License plate in Virginia. Sign up today at lfcplates.com $10 for standard, $20 personalized (plus fees)
1
5
7
Baby’s first time seeing Steven Gerard #MYPLmorning
1
7
Hashem A. Dbouk retweeted
David Brown@daveb0211
11 Jun 2021
Is this the worst ever presentation of live sport? #EURO2020 #ESPN
6
3
17
Novartis gene therapy Zolgensma cleared for use in Europe biopharmadive.com/news/novar… @BioPharmaDive #spinalmuscularatrophy #pharma #genetherapy #raredisease #novartis

Novartis gene therapy Zolgensma cleared for use in Europe

The Swiss pharma estimates 550 to 600 infants are born in Europe each year with spinal muscular atrophy, the hereditary disease Zolgensma treats.

biopharmadive.com
Happy birthday to the one and only @DivockOrigi #YNWA
Liverpool FC
@LFC
18 Apr 2020
𝙎𝙖𝙩𝙪𝙧𝙙𝙖𝙮 𝙣𝙞𝙜𝙝𝙩 𝙖𝙣𝙙 𝙄 𝙡𝙞𝙠𝙚 𝙩𝙝𝙚 𝙬𝙖𝙮 𝙮𝙤𝙪 𝙢𝙤𝙫𝙚, 𝘿𝙄𝙑𝙊𝘾𝙆 𝙊𝙍𝙄𝙂𝙄! 🤩🔥
1:13
Hashem A. Dbouk retweeted
Liverpool FC USA
@LFCUSA
8 Mar 2020
That James Milner magic 😍

0:29
37
316
3,571
In a CRISPR first, Editas therapy used to fix genes in the body #CRISPR #pharma biopharmadive.com/news/crisp… via @BioPharmaDive

In a CRISPR first, Editas therapy used to fix genes in the body

A patient with a severe type of inherited blindness was recently treated with Editas and Allergan's CRISPR medicine, marking the first in vivo use of the gene-editing technology in adults. 

biopharmadive.com
1
Bobbi!! #YNWA #bobbifirmino #LiverpoolFC
Liverpool FC
@LFC
25 Sep 2019
After receiving his milestone award... Enjoy Bobby's first 5⃣0⃣ @premierleague goals for the Reds 😍
3:47
Really Rapid Review of IAS 2019 Mexico City #HIV #HIVtherapy #IAS2019 blogs.jwatch.org/hiv-id-obse…
Hashem A. Dbouk retweeted
Nature Reviews Drug Discovery@NatRevDrugDisc
11 Jul 2019
This new Review discusses the different therapeutic approaches to develop oncolytic viruses for patients with cancer, including delivery modalities and methods for assessing their biological activity. Read more here go.nature.com/2XTc1NT @jsoriamd
25
41
At ASCO, debate over speedy drug approvals in the spotlight #cancertherapy #fda #ASCO #pharma biopharmadive.com/news/asco-… via @BioPharmaDive

At cancer conference, debate over speedy drug approvals in the spotlight

An unsuccessful Phase 3 study of Eli Lilly's Lartruvo made for an unusual feature in the ASCO annual meeting's top trial showcase.

biopharmadive.com
1
5 novel immuno-oncology targets to know before ASCO #cancer #ASCO #immunooncology biopharmadive.com/news/5-nov… via @BioPharmaDive

5 novel immuno-oncology targets to know before ASCO

Following checkpoint inhibitors is a tough act, but biopharma is hard at work with agents that could shut down other mechanisms cancer cells use to escape immune response.

biopharmadive.com
Clinical trials for protein "degrader" therapeutics #pharma #therapeutics #protein #cellbiology nature.com/articles/d41573-0…
AstraZeneca inks ambitious $6.9B deal for Daiichi cancer therapy #cancertherapy #pharma #astrazeneca biopharmadive.com/news/astra… via @BioPharmaDive

AstraZeneca inks ambitious $6.9B deal for Daiichi cancer therapy

The deal gives the British pharma access to an antibody-drug conjugate that the companies view as a challenger to several on-market cancer drugs. 

biopharmadive.com
After US FDA acceptance of BLA filing, Aimmune's peanut drug moves closer to European market #pharma #Aimmunetherapeutics #peanutallergy biopharmadive.com/news/aimmu… via @BioPharmaDive

Aimmune's peanut drug moves closer to European market

AR101 hit the primary endpoint of a Phase 3 European study, results Aimmune intends to include in a mid-year submission to the EMA.

biopharmadive.com
Biogen halts Alzheimer's drug trials in 'transformative' failure for the biotech #pharmanews #pharma #alzheimer #backtothedrawingboard biopharmadive.com/news/bioge… via @BioPharmaDive

Biogen halts Alzheimer's drug trials in major setback for biotech

Aducanumab, which targets beta-amyloid, was considered one of the most advanced therapies in clinical testing for the neurodegenerative disease, making its failure a blow to research efforts. 

biopharmadive.com
BIG pharma news: Bristol-Myers Squibb to buy Celgene for around $74 billion #pharma #BMS #Celgene firstwordpharma.com/node/161… via @fwpharma
Gilead, Agenus to partner on development of immuno-oncology therapies in deal potentially worth over $1.8 billion. #pharma #pharmanews #immunooncology #cancertherapy firstwordpharma.com/node/161… via @fwpharma
China becomes first country to approve AstraZeneca, FibroGen's anaemia drug roxadustat #anemia #CKD #china #pharma firstwordpharma.com/node/161… via @fwpharma
Load more